Thrombin topical (recombinant) - Biologic Drug Details

Summary for thrombin topical (recombinant)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for thrombin topical (recombinant) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for thrombin topical (recombinant) Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Baxter Healthcare Corporation	RECOTHROM	thrombin topical (recombinant)	For Solution	125248		2012-12-30	DrugPatentWatch analysis and company disclosures
Baxter Healthcare Corporation	RECOTHROM	thrombin topical (recombinant)	For Solution	125248		2015-06-05	DrugPatentWatch analysis and company disclosures
Baxter Healthcare Corporation	RECOTHROM	thrombin topical (recombinant)	For Solution	125248		2015-06-05	DrugPatentWatch analysis and company disclosures
Baxter Healthcare Corporation	RECOTHROM	thrombin topical (recombinant)	For Solution	125248		2028-06-13	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for thrombin topical (recombinant) Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for thrombin topical (recombinant)

Country	Patent Number	Estimated Expiration
Japan	5253501
Israel	202306
European Patent Office	2167041
Australia	2008266094
Spain	2397234
World Intellectual Property Organization (WIPO)	2008157304

Market Dynamics and Financial Trajectory for Recombinant Thrombin Topical

Last updated: August 16, 2025

Introduction

Recombinant thrombin topical, a hemostatic agent used to control bleeding during surgical procedures and trauma management, has experienced notable growth driven by advancements in biopharmaceutical manufacturing, an expanding surgical market, and increasing adoption across healthcare settings. This analysis examines the evolving market landscape, key factors influencing its financial trajectory, competitive dynamics, and future growth opportunities.

Market Overview

Recombinant thrombin topical emerged as a safer, recombinant alternative to traditional bovine-derived thrombin, addressing concerns about bovine spongiform encephalopathy (BSE) transmission and immunogenicity. Its primary application lies in surgeries—cardiac, vascular, orthopedic, and general procedures—where rapid hemostasis is critical. The global surgical hemostats market, including recombinant thrombin, is projected to reach approximately USD 2.5 billion by 2027, growing at a compound annual growth rate (CAGR) of 6.5% [1].

Market Drivers

1. Increasing Surgical Volume

Global surgical procedures are rising due to expanding aging populations and rising incidences of chronic conditions requiring operative interventions. The rise in cardiovascular surgeries, neurosurgeries, and orthopedic procedures directly correlates with increased demand for effective hemostatic agents. According to the World Health Organization, an estimated 234 million surgeries are performed annually worldwide, with the market for surgical hemostats expanding proportionally [2].

2. Safety and Efficacy Advantages

Recombinant thrombin offers enhanced safety over animal-derived products, eliminating risks associated with zoonotic transmissions. Its recombinant nature allows for consistent manufacturing and purity, boosting clinician confidence. Regulatory agencies such as the FDA have approved these products, facilitating wider adoption.

3. Technological Advancements

Improvements in recombinant protein production, formulation technologies, and delivery systems have increased the efficacy and shelf life of thrombin topical agents. Innovations have led to products offering rapid hemostasis with minimal complications, further driving market growth.

4. Regulatory and Reimbursement Policies

Clear regulatory pathways and reimbursement frameworks in key regions, such as the United States and Europe, support commercialization. Favorable policies incentivize product development and distribution, underpinning revenue growth.

Market Challenges

1. High Development and Manufacturing Costs

Recombinant protein production involves complex processes, high capital investments, and stringent quality controls, contributing to elevated costs. These costs influence pricing strategies and economic accessibility, especially in developing markets.

2. Competition from Alternative Hemostats

The market faces competition from other topical hemostatic agents, including oxidized cellulose, gelatin sponges, and fibrin sealants. The choice depends on efficacy, ease of use, cost, and surgeon preference.

3. Limited Long-term Clinical Data

While immediate hemostatic efficacy is well established, long-term safety and comparative effectiveness studies are still evolving. This limits some institutional adoption, especially in cost-sensitive environments.

Competitive Landscape

Globally, key players include:

• Johnson & Johnson (Ethicon)
• Baxter International
• Haemacure Corporation
• Octapharma AG

Johnson & Johnson's Ethicon brand, through its Surgiflo and Thrombin-JMI products, holds a significant share, leveraging its global distribution network. Baxter offers Thrombin-JMI, integrating recombinant thrombin in its hemostatic portfolio. The competition focuses on product purity, efficacy, cost competitiveness, and ease of application.

Financial Trajectory

Revenue Evolution

The recombinant thrombin topical market is forecasted to grow at a CAGR of approximately 7%, reaching USD 500 million globally by 2030 [1]. This growth trajectory is supported primarily by the expansion in surgical procedures and increasing preference for recombinant products over animal-derived options.

Pricing Trends

Pricing strategies are evolving to balance profitability and adoption. Premium pricing persists due to manufacturing complexities; however, market penetration initiatives and biosimilar-like strategies may exert downward pressure.

Investment and R&D

Pharmaceutical companies are investing in pipeline development of next-generation recombinant hemostats, focusing on enhanced biocompatibility and integrated delivery systems. R&D investments are critical to sustaining competitive advantage and addressing unmet clinical needs.

Market Penetration and Geographic Expansion

Developed regions, particularly North America and Europe, lead in adoption due to regulatory approval and healthcare infrastructure. Emerging markets, including Asia-Pacific and Latin America, present substantial growth opportunities owing to expanding healthcare access and surgical volumes. Market penetration rates vary depending on local regulatory pathways and economic factors.

Future Outlook

The recombinant thrombin topical market is positioned for sustained growth driven by technological innovation, increasing surgical demands, and favorable regulatory environments. Potential disruptions include the emergence of novel hemostatic agents or biosimilar products that could influence pricing and market share dynamics.

Advances in recombinant DNA technology and bioengineering are expected to enhance product formulations, reduce costs, and improve patient outcomes. Integrating recombinant thrombin into combination products or delivery devices could further expand its clinical utility and market reach.

Key Factors Influencing Financial Trajectory

• Regulatory Approval and Reimbursement Policies: Streamlined approval processes and reimbursement coverage will accelerate adoption rates.
• Cost Management: Economies of scale and technological innovation will be critical in lowering manufacturing costs, thereby optimizing profitability.
• Market Differentiation: Product differentiation via efficacy, safety profile, and ease of use will continue to influence purchasing decisions.
• Global Expansion: Entry into emerging markets offers substantial revenue opportunities but requires navigating local regulatory landscapes.

Conclusion

Recombinant thrombin topical's market dynamics are shaped by an interplay of technological advancements, clinical needs, regulatory frameworks, and economic factors. Its promising financial trajectory hinges on ongoing innovation, strategic market entry, and competitive positioning. Stakeholders that capitalize on these trends are poised for significant growth in an expanding global surgical hemostats landscape.

---

Key Takeaways

• Growing Surgical Procedures: An aging global population and rising chronic disease prevalence are fueling demand.
• Safety and Efficacy Edge: Recombinant thrombin's safety profile surpasses traditional animal-derived products.
• Regulatory and Market Expansion: Clear regulatory pathways and emerging markets offer growth opportunities.
• Cost and Competition: High manufacturing costs and competition from alternative hemostats remain challenges.
• Innovation Is Critical: Continuous R&D and product differentiation will determine future market share and profitability.

---

FAQs

Q1: What distinguishes recombinant thrombin topical from traditional bovine thrombin?
A1: Recombinant thrombin is produced using genetically engineered cells, eliminating the risk of zoonotic transmissions and immunogenic reactions associated with bovine sources, while offering consistent purity and supply.

Q2: Which regions are the primary drivers of market growth?
A2: North America and Europe are leading due to advanced healthcare infrastructure, while Asia-Pacific and Latin America are emerging markets with substantial growth potential.

Q3: How does competition impact the pricing of recombinant thrombin products?
A3: Competition from alternative hemostatic agents and biosimilar entrants exerts downward pressure on prices, prompting manufacturers to innovate and differentiate their offerings.

Q4: What are the main challenges in commercializing recombinant thrombin topical?
A4: High manufacturing costs, regulatory hurdles, and limited long-term safety data are primary challenges impacting market penetration and acceptance.

Q5: What is the expected timeline for the market to reach USD 500 million globally?
A5: The market is projected to achieve this milestone by 2030, with a CAGR of approximately 7%, driven by increasing surgical volume and technological advancements.

---

References

[1] Market Research Future. "Global Surgical Hemostats Market Analysis & Forecast to 2027."

[2] World Health Organization. "Global Surgery Data."